Amgen Denies Rumors About PCSK9 Inhibitors

Amgen says there is no truth to the rumor that the FDA is investigating post-marketing reports of serious brain infections in patients taking PCSK9 inhibitors. The Amgen statement was in response to this anonymous post on CafePharma: “The FDA informed Amgen and Regeneron today that there have been a number of post marketing reports of...Click here to continue reading...

Source: CardioBrief - December 20, 2015 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes People, Places & Events Policy & Ethics PCSK9 Amgen Sanofi Regeneron Repatha Praluent Source Type: blogs